Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells.


Journal

Advances in biological regulation
ISSN: 2212-4934
Titre abrégé: Adv Biol Regul
Pays: England
ID NLM: 101572336

Informations de publication

Date de publication:
01 2019
Historique:
received: 06 10 2018
revised: 15 10 2018
accepted: 16 10 2018
pubmed: 27 10 2018
medline: 5 3 2020
entrez: 27 10 2018
Statut: ppublish

Résumé

Berberine (BBR) is a common nutraceutical consumed by millions worldwide. BBR has many different effects on human health, e.g., diabetes, diarrhea, inflammation and now more recently it has been proposed to have potent anti-cancer effects. BBR has been shown to suppress the growth of cancer cells more than normal cells. BBR has been proposed to exert its growth-inhibitory effects by many different biochemical mechanisms including: suppression of cell cycle progression, induction of reactive oxygen species, induction of apoptosis and autophagy and interactions with DNA potentially leading to DNA damage, and altered gene expression. Pancreatic cancer is a leading cancer worldwide associated with a poor prognosis. As our population ages, pancreatic cancer has an increasing incidence and will likely become the second leading cause of death from cancer. There are few truly-effective therapeutic options for pancreatic cancer. Surgery and certain chemotherapeutic drugs are used to treat pancreatic cancer patients. Novel approaches to treat pancreatic cancer patients are direly needed as they usually survive for less than a year after being diagnosed. In the following manuscript, we discuss the abilities of BBR and certain chemically-modified BBRs (NAX compounds) to suppress growth of pancreatic cancer cells.

Identifiants

pubmed: 30361003
pii: S2212-4926(18)30149-0
doi: 10.1016/j.jbior.2018.10.003
pii:
doi:

Substances chimiques

DNA, Neoplasm 0
Berberine 0I8Y3P32UF

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

172-182

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Stephen L Abrams (SL)

Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, 27858, USA.

Matilde Y Follo (MY)

Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy.

Linda S Steelman (LS)

Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, 27858, USA.

Kvin Lertpiriyapong (K)

Department of Comparative Medicine, Brody School of Medicine at East Carolina University, USA; Center of Comparative Medicine and Pathology, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medicine and the Hospital for Special Surgery, New York City, NY, USA.

Lucio Cocco (L)

Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy.

Stefano Ratti (S)

Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy.

Alberto M Martelli (AM)

Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy.

Saverio Candido (S)

Department of Biomedical and Biotechnological Sciences - Oncological, Clinical and General Pathology Section, University of Catania, Catania, Italy.

Massimo Libra (M)

Department of Biomedical and Biotechnological Sciences - Oncological, Clinical and General Pathology Section, University of Catania, Catania, Italy.

Ramiro M Murata (RM)

Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, 27858, USA; Department of Foundational Sciences, School of Dental Medicine, East Carolina University, USA.

Pedro L Rosalen (PL)

Department of Physiological Sciences, Piracicaba Dental School, State University of Campinas, Piracicaba, Brazil.

Giuseppe Montalto (G)

Biomedical Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy; Consiglio Nazionale delle Ricerche, Istituto di Biomedicina e Immunologia Molecolare "Alberto Monroy", Palermo, Italy.

Melchiorre Cervello (M)

Consiglio Nazionale delle Ricerche, Istituto di Biomedicina e Immunologia Molecolare "Alberto Monroy", Palermo, Italy.

Agnieszka Gizak (A)

Department of Molecular Physiology and Neurobiology, Wroclaw University, Wroclaw, Poland.

Dariusz Rakus (D)

Department of Molecular Physiology and Neurobiology, Wroclaw University, Wroclaw, Poland.

Weifeng Mao (W)

College of Basic Medical Sciences, Dalian Medical University, Dalian, Liaoning, China.

Paolo Lombardi (P)

Naxospharma, Via Giuseppe di Vittorio 70, Novate Milanese, 20026, Italy.

James A McCubrey (JA)

Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, 27858, USA. Electronic address: mccubreyj@ecu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH